



Syncom Formulations (India) Limited

A WHO-GMP & ISO 9001-2008 Certified Company

CIN L24239MH1988PLC047759

SYNCOM/SE/2017

11th Jan, 2017

To,
The General Manager
DCS-CRD
BSE Ltd.
Rotunda Building
P.J. Tower, Dalal Street, Fort
MUMBAI - 400001

[Online filing at listing.bseindia.com](http://online.filing.at.listing.bseindia.com)

BSE CODE:524470

Sub: Filing of Statement relating to Investors Complaints as per Regulation 13(3) of the SEBI (LODR) Regulations, 2015 for the Quarter Ended 31st December, 2016.

Dear Sir/Madam,

In reference to Regulation 13(3) of the SEBI Listing Regulations, we hereby submit the Statement for the Investors Complaints for the Quarter ended 31st December, 2016 as under:

S.No.	Particulars	Comments
1.	No. of Complaints Pending at the beginning of the quarter	0
2.	No. of Complaints Received during the quarter	21
3.	No. of Complaints Disposed off during the quarter	19
4.	No. of Complaints Remained unresolved at the end of the quarter	2

It may please be noted that the aforesaid report is based on the information provided by the Registrar and Share Transfer Agent as well as the complaints directly received by the Company and/or forwarded by the SEBI or BSE. The aforesaid statement shall also be placed before the Board at the next Board meeting.

You are requested to please take on record the above said document for your reference and further needful.

Thanking You,
Yours Faithfully,

FOR, SYNCOM FORMULATIONS (INDIA) LTD.

CS NAFISA VAKIL
COMPANY SECRETARY &
COMPLIANCE OFFICER

Bringing a smile on every face...